Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MODIFI-IBD trial of modafinil for severe fatigue in quiescent inflammatory bowel disease
NL-OMON61102Phase 3Not yet recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Inflammatory bowel disease-associated fatigue (IBD-F) comparing Modafinil with Placebo (2 arms). Primary endpoint: Change in IBD-F section I at week 8. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
modafinil
03
Conditions
Inflammatory bowel disease-associated fatigue (IBD-F)
Beyond the preview
Go deeper on NL-OMON61102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61102.